Literature DB >> 25642355

A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease.

Paul Zarogoulidis1, Ioannis Kioumis2, Theodora Tsiouda3, Nikolaos Pezirkianidis4, Christos Ritzoulis5, Haidong Huang6, Wolfgang Hohenforst-Schmidt7, Dionysios Spyratos2, Konstantinos Porpodis2, Georgia Pitsiou2, Sofia Lampaki2, John Organtzis2, Bianca Kathryn Malecki8, Sindre Ervik Saetre9, Konstantinos Zarogoulidis2, Marek Malecki10.   

Abstract

INTRODUCTION: Cystic Fibrosis (CF), Ulcerative Colitis (UC), and Crohn's Disease (CD) manifest as various, multiple symptoms from malfunctioning and/or damaged gastrointestinal tract, which plague the patients. These symptoms result from the dysfunctional expression products of the specific mutations of the genes, which either manifest upon birth (CF) or later in life in immuno-genetically susceptible individuals as inflammatory bowel diseases (IBD). They all may potentially lead to malnutrition of the patients. Since only correcting the mutated genes, may cure these diseases permanently, the works on the future safe gene therapies continue vigorously. However, provision of the necessary nutrients to the suffering patients is the requirement for an effective, supportive care at present. In this realm, we have developed a model of the diseased gastrointestinal tract aimed to guide designing and testing various nutritional therapies.
MATERIALS AND METHODS: It is well known that inflammatory bowel diseases induce crypts within the patients' gastrointestinal tract. Therefore, we have bioengineered, a novel, three-dimensional model of the gastrointestinal tract to evaluate the rheology of different types of nutrients. The model was assembled out of the bio-inert polymer tube with openings leading to vials of different shapes and sizes, as the simulation of the gastrointestinal tract altered by the diseases to contain multiple crypts. RESULTS AND
CONCLUSIONS: The newly developed three-dimensional model effectively simulates the structure and functions of the gastrointestinal tract of the patients with mild and severe Ulcerative Colitis, Crohn's Disease, and Cystic Fibrosis. This model should allow us to design and test different nutritional supplements, with properties complementing the pathologically altered by the diseases functionalities of the patients' gastrointestinal tracts. Therefore, it should help us to design the effective supportive therapies; thus to prevent the patients' malnutrition.

Entities:  

Keywords:  Crohn`s Disease; Cystic Fibrosis; Ulcerative Colitis; bioengineering; biotechnology; gene therapy; inflammatory bowel disease (IBD); malnutrition; nutrition model

Year:  2014        PMID: 25642355      PMCID: PMC4309388          DOI: 10.4172/2155-983X.1000128

Source DB:  PubMed          Journal:  J Nanomedine Biotherapeutic Discov        ISSN: 2155-983X


  20 in total

1.  Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2004-07       Impact factor: 10.864

Review 2.  Ulcerative colitis.

Authors:  Silvio Danese; Claudio Fiocchi
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

Review 3.  Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.

Authors:  R Balfour Sartor
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-07

Review 4.  Innate immunity in Crohn's disease: the reverse side of the medal.

Authors:  Rodrigue Dessein; Mathias Chamaillard; Silvio Danese
Journal:  J Clin Gastroenterol       Date:  2008-09       Impact factor: 3.062

5.  Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.

Authors:  Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Randall L Rosenblatt; Lynne Quittell; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2010-08-01       Impact factor: 21.405

Review 6.  Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation.

Authors:  Jean-Daniel Lalande; Marcel A Behr
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

7.  Consumption of refined sugar by patients with Crohn's disease, ulcerative colitis, or irritable bowel syndrome.

Authors:  G Järnerot; I Järnmark; K Nilsson
Journal:  Scand J Gastroenterol       Date:  1983-11       Impact factor: 2.423

8.  Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum.

Authors:  Martin Baumgart; Belgin Dogan; Mark Rishniw; Gil Weitzman; Brian Bosworth; Rhonda Yantiss; Renato H Orsi; Martin Wiedmann; Patrick McDonough; Sung Guk Kim; Douglas Berg; Ynte Schukken; Ellen Scherl; Kenneth W Simpson
Journal:  ISME J       Date:  2007-07-12       Impact factor: 10.302

9.  Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan.

Authors:  R Shoda; K Matsueda; S Yamato; N Umeda
Journal:  Am J Clin Nutr       Date:  1996-05       Impact factor: 7.045

10.  The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease.

Authors:  Andrew P Cuthbert; Sheila A Fisher; Muddassar M Mirza; Kathy King; Jochen Hampe; Peter J P Croucher; Silvia Mascheretti; Jeremy Sanderson; Alastair Forbes; John Mansfield; Stefan Schreiber; Cathryn M Lewis; Christopher G Mathew
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

View more
  1 in total

1.  Validation and Optimization of an Ex Vivo Assay of Intestinal Mucosal Biopsies in Crohn's Disease: Reflects Inflammation and Drug Effects.

Authors:  Kasper Vadstrup; Elisabeth Douglas Galsgaard; Jens Gerwien; Marianne Kajbæk Vester-Andersen; Julie Steen Pedersen; Julie Rasmussen; Søren Neermark; Marianne Kiszka-Kanowitz; Teis Jensen; Flemming Bendtsen
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.